CGEM News and Press, Cullinan Oncology Inc.

2024-06-09 09:44:11 ET Summary Cullinan Therapeutics, Inc. has seen a recent pullback in its shares, but they are still up 50% since mid-April after rebranding and focusing on autoimmune diseases. The company's lead asset is zipalertinib, an oral EGFR inhibitor being evaluated in ...

CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc . (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in patients receiving zipalertinib after prior treatment with amivanta...

2024-05-29 21:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc . (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer and Jeffrey Jones, MD, MBA, Chief Medical Officer, ...

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer (NSCLC) with oncogenic mutations Longer term follow-up for pati...

2024-05-16 16:42:47 ET More on Cullinan Therapeutics Amgen’s Blincyto data send Cullinan higher Cullinan Therapeutics expands into autoimmune diseases Seeking Alpha’s Quant Rating on Cullinan Therapeutics Read the full article on Seeking Alpha...

2024-05-16 11:10:51 ET More on Cullinan Oncology Amgen’s Blincyto data send Cullinan higher Cullinan Therapeutics expands into autoimmune diseases Seeking Alpha’s Quant Rating on Cullinan Oncology Historical earnings data for Cullinan Oncology ...

Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases, starting with systemic lupus erythematosus (SLE) as the first indication Cash...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...